According to the American Headache Society, more than thirty-seven million Americans suffer from migraine attacks. Of these, approximately 4 million have chronic migraine headaches and 10 to 14 days a month.
While some people may be helped by low-cost, over-the-counter medications such as ibuprofen, other prescriptive medications, such as sumatriptan and ergotamine, may be needed to constrict blood vessels in the brain and cause dizziness or nausea. Botox injections are also used to relieve migraines in some people.
But a large percentage of those affected are helped by nothing.
"This is the first mechanism specific migraine drug designed for prevention," said lead study author Dr. Peter Goadsby, a professor of neurology at Kings College London, UK and the University of California, San Francisco Modifying migraine treatment for those who do not respond to conventional treatments. "
Published in the run-up to the annual meeting of the American Academy of Neurology ̵
Researchers have found that the drug reduces the average number of monthly migraine headaches by more than 50 percent for nearly a third of study participants Months, patients with the human antibody beha Nearly three times as likely, their migraine days were reduced by 50 percent or more than those treated with placebo
They also had a greater average reduction in the number of days with headache and the number of days they needed to take medication to stop the migraine.
No pat patients taking erenumab stopped treatment due to side effects, but scientists found that more research was needed to investigate whether the benefits persisted. Denise Desjardins, 58, with niece Madeline Salvitella, has been suffering from migraines for more than 10 years, but found great relief after taking erenumab, a fully human monoclonal antibody promising in migraine prophylaxis.
The 58-year-old Malden, Massachusetts, coped with migraine headaches over 10 years ago, especially around her menstrual cycle.
"I would be in bed for two to three days, four to five times a year," said Desjardins. "These were in bed, no matter what a headache."
Her migraine became a daily misery after a bilateral mastectomy after a diagnosis of breast cancer. It's based on imitrex, a popular migraine drug that helps to soothe overactive pain nerves in the brain, but it did not help.
For about four years, Desjardins takes an erenumab injection once every month without any side effects, as part of the study.
"I do not even think I can get more migraines," said Desjardins.
The drug is expected to receive approval from the Food and Drug Administration on May 17, it could become available for prescription and insurance coverage later this year. The cost of the drug was estimated at $ 10,000 a year.
Because other migraine medicines were not developed for headaches, their side effects were limited to how well patients tolerated them, Kudrow said.
"This class of drugs is a real game changer," Kudrow said. "One, because it's effective and two, the side effect profile is really cheap."